anilino-p-tolyl-acetic acid | 73842-43-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: anilino-p-tolyl-acetic acid
• 英文别名: Anilino-p-tolyl-essigsaeure；2-(p-tolyl)-2-phenylaminoacetic acid；Phenylamino-p-tolyl-acetic acid；2-anilino-2-(4-methylphenyl)acetic acid
• CAS: 73842-43-0
• 化学式: C₁₅H₁₅NO₂
• mdl: MFCD04116967
• 分子量: 241.29
• InChiKey: WWWQXEUOJFAILN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.133
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-溴-N-羟基-2-(对甲苯基)乙酰胺 在 sodium hydroxide 作用下， 以 1,4-二氧六环 、 乙腈 为溶剂， 反应 27.0h， 生成 anilino-p-tolyl-acetic acid
  参考文献：
  名称：

  异羟肟酸的简单合成及其转化为α-羟基和α-氨基酸

  摘要：

  在羟基胺衍生物的存在下，LiBr或Li 2 NiBr 4对宝石-二氰基环氧化合物的亲核开环会导致新的α-卤代异羟肟酸。这些化合物已经以良好的产率用于合成α-官能化的异羟肟酸，α-羟基和α-氨基酸。

  DOI：

  10.1016/s0040-4039(00)00228-8

文献信息

• Novel heterocycles as inhibitors of leucocyte adhesion and as VLA-4 antagonists
  申请人：——

  公开号：US20020065391A1

  公开（公告）日：2002-05-30

  The present invention relates to compounds of the formula I 1 which are inhibitors of the adhesion and migration of leucocytes and/or antagonists of the adhesion receptor VLA-4 which belongs to the group of integrins. The invention also relates to processes for their preparation, to the use of compounds of the formula I for the treatment or prophylaxis of diseases which are caused by an undesired extent of leucocyte adhesion and/or leucocyte migration or which are associated therewith or in which cell-cell or cell-matrix interactions which are based on interactions of VLA-4 receptors with their ligands play a part, for example of inflammatory processes, of rheumatoid arthritis or of allergic disorders, and also to the use of compounds of the formula I for the production of pharmaceuticals for use in such diseases, and to pharmaceutical preparations which contain the compounds of the formula I.

  本发明涉及式I的化合物，该化合物是白细胞粘附和迁移的抑制剂和/或属于整合素群的粘附受体VLA-4的拮抗剂。该发明还涉及它们的制备方法，化合物式I用于治疗或预防由于白细胞粘附和/或白细胞迁移的不良程度引起的疾病，或与之相关的疾病，或基于VLA-4受体与其配体相互作用而发挥作用的细胞-细胞或细胞-基质相互作用的疾病，例如炎症过程、类风湿关节炎或过敏性疾病，以及化合物式I用于生产用于此类疾病的药物，以及含有化合物式I的药物制剂。
• 5-Membered ring heterocycles as inhibitors of leucocyte adhesion and as VLA-4 antagonists
  申请人：Aventis Pharma Deutschland GmbH

  公开号：US20040220148A1

  公开（公告）日：2004-11-04

  Compounds of the formula I 1 in which B, D, E, R, W, Y, Z, b, c, d, e, f, g and h have the meanings indicated in the claims, are inhibitors of the adhesion and migration of leucocytes and/or antagonists of the adhesion receptor VLA-4 which belongs to the group of integrins. The invention relates to the use of compounds of the formula I and of pharmaceutical preparations which contain such compounds for the treatment and prophylaxis of diseases which are caused by an undesired extent of leucocyte adhesion and/or leucocyte migration or which are associated therewith or in which cell-cell or cell-matrix interactions which are based on interactions of VLA-4 receptors with their ligands play a part, for example of inflammatory processes, of rheumatoid arthritis or of allergic disorders, and it also relates to the use of compounds of the formula I for the production of pharmaceuticals for use in such diseases. It further relates to novel compounds of the formula I.

  公式I中B、D、E、R、W、Y、Z、b、c、d、e、f、g和h具有索引中指示的含义，是白细胞粘附和迁移的抑制剂和/或属于整合素群的粘附受体VLA-4的拮抗剂。本发明涉及公式I化合物的使用以及含有这种化合物的药物制剂，用于治疗和预防由白细胞粘附和/或白细胞迁移的不良程度引起的疾病，或与之相关的疾病，或基于VLA-4受体与其配体相互作用的细胞-细胞或细胞-基质相互作用在其中起作用的炎症过程、类风湿关节炎或过敏性疾病等，还涉及公式I化合物用于生产用于治疗此类疾病的药物。此外，还涉及公式I的新化合物。
• Bis(trifluoromethyl)hydantoins as intermediates for pharmaceutically active ingredients
  申请人：——

  公开号：US20020183374A1

  公开（公告）日：2002-12-05

  The present invention relates to hydantoins of formula I, 1 in which R is the residue of an amino carboxylic acid or of an amino carboxylic acid derivative, which is obtained formally by removing an NH 2 group from an amino carboxylic acid or an amino carboxylic acid derivative, to the preparation thereof and to the use thereof as intermediates, in particular for preparing pharmaceutically active ingredients.

  本发明涉及公式I的咪唑啉，其中R是氨基羧酸或氨基羧酸衍生物的残基，其形式上是通过从氨基羧酸或氨基羧酸衍生物中去除NH2基团而获得的，以及其制备和用作中间体的用途，特别是用于制备药用活性成分。
• Naphthyridine derivatives, processes for their preparation, their use, and pharmaceutical compositions comprising them
  申请人：Aventis Pharma Deutschland GmbH

  公开号：EP1065207A1

  公开（公告）日：2001-01-03

  The present invention relates to compounds of the formula I, in which B, G, Z, X, Y, r, s and t have the meanings indicated in the claims, their physiologically tolerable salts and their prodrugs. The compounds of the formula I are valuable pharmacologically active compounds. They are vitronectin receptor antagonists and inhibitors of cell adhesion and are suitable for the therapy and prophylaxis of illnesses which are based on the interaction between vitronectin receptors and their ligands in cell-cell or cell-matrix interaction processes or which can be prevented, alleviated or cured by influencing such interactions. For example, they can be applied for inhibiting bone resorption by osteoclasts and thus for treating and preventing osteoporosis, or for inhibiting undesired angiogenesis or proliferation of cells of the vascular smooth musculature. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical compositions comprising them.

  本发明涉及公式I的化合物， 其中B、G、Z、X、Y、r、s和t具有索引中指示的含义，它们的生理耐受盐和前药。公式I的化合物是有价值的药理活性化合物。它们是维脱蛋白受体拮抗剂和细胞粘附抑制剂，适用于基于维脱蛋白受体与其配体在细胞-细胞或细胞-基质相互作用过程中的相互作用而导致的疾病的治疗和预防，或者可以通过影响这种相互作用来预防、缓解或治愈。例如，它们可用于通过抑制破骨细胞来抑制骨吸收，从而治疗和预防骨质疏松症，或者用于抑制不良血管生成或血管平滑肌细胞增殖。此外，本发明还涉及公式I化合物的制备方法，它们的用途，特别是作为药物中的活性成分，以及包含它们的药物组合物。
• Novel imidazolidine derivatives, their preparation and their use
  申请人：——

  公开号：US20030109497A1

  公开（公告）日：2003-06-12

  The present invention relates to novel imidazolidine derivatives of the formula I, 1 in which B, E, W, Y, R, R 2 , R 3 , R 30 , e and h have the meanings given herein. The compounds of the formula I are valuable pharmaceutically active compounds which are suitable, for example, for treating inflammatory diseases, for example, rheumatoid arthritis, or allergic diseases. The compounds of the formula I are inhibitors of the adhesion and migration of leukocytes and/or antagonists of the adhesion receptor VLA-4, which belongs to the integrin group. They are generally suitable for treating diseases which are caused by, or associated with, an undesirable degree of leukocyte adhesion and/or leukocyte migration or in which cell-cell or cell-matrix interactions, which are based on the interactions of VLA-4 receptors with their ligands, play a role. The invention furthermore relates to processes for preparing the compounds of the formula I, to their use and to pharmaceutical preparations which comprise compounds of the formula I.

  本发明涉及公式I的新型咪唑啉衍生物，其中B、E、W、Y、R、R2、R3、R30、e和h的含义如本文所述。公式I的化合物是有价值的药物活性化合物，例如，适用于治疗炎症性疾病，例如类风湿性关节炎或过敏性疾病。公式I的化合物是白细胞的黏附和迁移的抑制剂和/或黏附受体VLA-4的拮抗剂，该受体属于整合素组。它们通常适用于治疗由白细胞黏附和/或白细胞迁移的不良程度引起或与之相关的疾病，或在其中基于VLA-4受体与其配体的相互作用的细胞-细胞或细胞-基质相互作用发挥作用。此外，本发明还涉及制备公式I的化合物的方法，它们的用途以及包括公式I的化合物的制药制剂。